MDGL
Madrigal Pharmaceuticals, Inc.
MDGL has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over MDGL overall, supported by stronger fundamentals and stronger modeled upside.
MDGL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
MDGL's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MDGL PE Valuation
MDGL has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 87x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MDGL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect MDGL to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
MDGL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.89 | — |
| Q3 2026 | -$5.96 | +$6.84 |
| Q2 2026 | -$12.87 | -$0.23 |
| Q1 2026 | -$12.78 | +$5.06 |
| Q4 2025 | -$12.85 | +$9.05 |
| Q3 2025 | -$12.80 | +$12.28 |
| Q2 2025 | -$12.64 | +$12.86 |
| Q1 2025 | -$17.84 | +$5.25 |
| Q4 2024 | -$21.90 | -$1.96 |
MDGL is still losing money, but far less than before: $5.96 per share over the past year, against $25.50 at its worst in mid-2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over MDGL on earnings quality, reporting a profit while its opponent remains loss making.
MDGL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $431.3M | +50% |
| Q2 2026 | $364.3M | +71% |
| Q1 2026 | $311.3M | +127% |
| Q4 2025 | $321.1M | +211% |
| Q3 2025 | $287.3M | +362% |
| Q2 2025 | $212.8M | +1354% |
MDGL's revenue has grown year over year for 10 quarters in a row: $431M last quarter, up 50% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +53 points |
| Q2 2026 | -15% | +6.7 points |
| Q1 2026 | -30% | +28 points |
| Q4 2025 | -19% | +46 points |
| Q3 2025 | -40% | +147 points |
| Q2 2025 | -22% | +1088 points |
| Q1 2025 | -58% | N/A |
| Q4 2024 | -65% | N/A |
MDGL has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
MDGL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $116.6M | +48% |
| Q2 2026 | $19.1M | +$66.1M |
| Q1 2026 | -$171.3M | -$82.4M |
| Q4 2025 | -$133.1M | -$28.4M |
| Q3 2025 | $79M | +$146.8M |
| Q2 2025 | -$47.1M | +$88M |
| Q1 2025 | -$88.9M | +$60.6M |
| Q4 2024 | -$104.7M | -$23.7M |
MDGL has burned cash in almost every quarter: −$169M over the past year, against −$162M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MDGL on cash generation, producing positive trailing cash flow while its opponent burns cash.
MDGL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4% | +1.2M shares |
| 1 year | +35% | +7.8M shares |
| 3 years | +64% | +11.8M shares |
| 5 years | +82% | +13.7M shares |
| Available history | +96% | +14.9M shares |
MDGL has 30M diluted shares, up 35% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over MDGL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MDGL Net Leverage
MDGL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
MDGL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 21.0 | Neutral |
MDGL's weekly RSI is 38 (neutral) and its Stochastic is 21 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MDGL PE vs Healthcare Sector
MDGL has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MDGL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $453.4 | 6.2% below |
| 20 week MA | $496.6 | 14% below |
| 50 week MA | $503.0 | 15% below |
| 100 week MA | $431.1 | 1.4% below |
| 200 week MA | $334.7 | 27% above |
MDGL has fallen below most of its moving averages, though it's still 27% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over MDGL on trend strength, trading above more of its moving averages.
MDGL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.2 | $120.1 | +29% |
| 2021 | $120.1 | $87.3 | -27% |
| 2022 | $87.3 | $273.6 | +213% |
| 2023 | $273.6 | $231.4 | -15% |
| 2024 | $231.4 | $313.1 | +35% |
| 2025 | $313.1 | $598.9 | +91% |
| 2026 YTD | $598.9 | $425.2 | -29% |
MDGL has finished higher in four of the last six years, two of them by more than 50%. It's down 29% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MDGL on returns for 2026, with the stronger performance.